Calpain-like proteins in trypanosomatids: Effects of calpain inhibitors on the parasites' physiology and motivations for their possible application as chemotherapeutic agents

Cystatins: Protease Inhibitors, Biomarkers and Immunomodulators

Volumn , Issue , 2011, Pages 77-104

  dos Santos, André Luis Souza ^a,b   d'Avila Levy, Claudia Masini ^a,b   Branquinha, Marta Helena ^a,b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Calpain; Calpain inhibitors; Chemotherapy; Development; Leishmania; Trypanosoma; Trypanosomatids; Virulence

Indexed keywords

EID: 84892007139     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (130)

1. Sorimachi, H.; Ishiura, S. and Suzuki, K. (1997). Structure and physiological function of calpains. Biochem. J., 328 721-732.
2. Goll, D. E.; Thompson, V. F.; Li, H.; Wei, W. and Cong, J. (2003). The calpain system. Physiol. Rev., 83 731-801.
3. 2+-dependent protease activity and a novel mode of enzyme activation. EMBO J., 18 6880-6889.
4. Carragher, N. O. (2006). Calpain inhibitors: a therapeutic strategy targeting multiple disease states. Curr. Pharmac. Des., 12 615-638.
5. Croall, D. E. and Ersfeld, K. (2007). The calpains: modular designs and functional diversity. Gen. Biol., 8 1-11.
6. Strobl, S.; Fernandez-Catalan, C.; Braun, M.; Huber, R.; Masumoto, H.; Nakagawa, K.; Irie, A.; Sorimachi, H.; Bourenkow, G.; Bartunik, H.; Suzuki, K. and Bode, W. (2000). The crystal structure of calcium-free human m-calpain suggests an electrostatic switch mechanism for activation by calcium. Proc. Natl. Acad. Sci. USA, 97 588-592.
7. Dutt, P.; Arthur, J. S.; Grochulski, P.; Cygler, M. and Elce, J. S. (2000). Roles of individual EF-hands in the activation of m-calpain by calcium. Biochem. J., 348 37-43.
8. 2+-dependent cysteine protease. FEBS Lett., 501 111-114.
9. Arthur, J. S. and Crawford, C. (1996). Investigation of the interaction of m-calpain with phospholipids: calpain-phospholipid interactions. Biochim. Biophys. Acta, 1293 201-206.
10. 2+-regulated phospholipid-binding domain. Biochem. Biophys. Res. Commun., 280 1333-1339.
11. Friedrich, P. and Bozóky, Z. (2005). Digestive versus regulatory proteases: on calpain action in vivo. Biol. Chem., 386 609-612.
12. Huang, Y. and Wang, K. K. (2001). The calpain family and human disease. Trends Mol. Med., 7 355-362.
13. Zatz, M. and Starling, A. (2005). Calpains and disease. N. Engl. J. Med., 352 2413-2423.
14. Bertipaglia, I. and Carafoli, E. (2007). Calpains and human disease. Subcell. Biochem., 45 29-53.
15. Crawford, C.; Brown, N. R. and Willis, A. C. (1993). Studies of the active site of mcalpain and the interaction with calpastatin. Biochem. J., 296 135-142.
16. Todd, B.; Moore, D.; Deivanayagan, C. C.; Lin, G. D.; Chattopadhyay, D.; Maki, M.; Wang, K. K. and Narayana, S. V. (2003). A structural model for the inhibition of calpain by calpastatin: crystal structures of the native domain VI of calpain and its complexes with calpastatin peptide and a small molecule inhibitor. J. Mol. Biol., 328 131-146.
17. Maki, M.; Takano, E.; Mori, H.; Kannagi, R.; Murachi, T. and Hatanaka, M. (1987). Repetitive region of calpastatin is a functional unit of the proteinase inhibitor. Biochem. Biophys. Res. Commun., 143 300-308.
18. Takano, J.; Watanabe, M.; Hitomi, K. and Maki, M. (2000). Four types of calpastatin isoforms with distinct amino-terminal sequences are specified by alternative first exons and differentially expressed in mouse tissues. J. Biochem., 128 83-92.
19. Adachi, Y.; Ishida-Takahashi, A.; Takahashi, C.; Takano, E.; Murachi, T. and Hatanaka, M. (1991). Phosphorylation and subcellular distribution of calpastatin in human hematopoietic system cells. J. Biol. Chem., 266 3968-3972.
20. Averna, M.; De Tullio, R.; Salamino, F.; Melloni, F. and Pontremoli, S. (1999). Phosphorylation of rat brain calpastatins by protein kinase C. FEBS Lett., 450 13-16.
21. Tullio, R. D.; Passalacqua, M.; Averna, M.; Salamino, F.; Melloni, E. and Pontremoli, S. (1999). Changes in intracellular localization of calpastatin during calpain activation. Biochem. J., 343 467-472.
22. Averna, M.; Tullio, R. D.; Passalacqua, M.; Salamino, F.; Pontremoli, S. and Melloni, E. (2001). Changes in intracellular calpastatin localization are mediated by reversible phosphorylation. Biochem. J., 354 25-30.
23. Lane, R. D.; Allan, D. M. and Mellgren, R. L. (1992). A comparison of the intracellular distribution of mu-calpain, m-calpain and calpastatin in proliferating human A431 cells. Exp. Cell Res., 203 5-16.
24. Sorimachi, Y.; Harada, K.; Saido, T. C.; Ono, T.; Kawashima, S. and Yoshida, K. (1997). Downregulation of calpastatin in rat heart after brief ischemia and reperfusion. J. Biochem., 122 743-748.
25. Mimori, T.; Suganuma, K.; Tanami, Y.; Nojima, T.; Matsumura, M.; Fuji, T.; Yoshizawa, T.; Suzuki, K. and Akizuki, M. (1995). Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases. Proc. Natl. Acad. Sci. USA, 92 7267-7271.
26. Newcomb, J. K.; Pike, B. R.; Zhao, X.; Banik, N. L. and Hayes, R. L. (1999). Altered calpastatin protein levels following traumatic brain injury in rat. J. Neurotrauma, 16 1-11.
27. Bardsley, R. G.; Allcock, S. M.; Dawson, J. M.; Dumelow, N. W.; Higgins, J. A.; Lasslett, Y. V.; Lockley, A. K.; Parr, T. and Buttery, P. J. (1992). Effect of beta-agonists on expression of calpain and calpastatin activity in skeletal muscle. Biochemie, 74 267-273.
28. Tidball, J. G. and Spencer, M. J. (2002). Expression of calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse. J. Physiol., 545 819-828.
29. Saez, M. E.; Ramirez-Lorca, R.; Moron, F. J. and Ruiz, A. (2006). The therapeutic potential of the calpain family: new aspects. Drug Discov. Today, 11 917-923.
30. Donkor, I. O. (2000). A survey of calpain inhibitors. Curr. Med. Chem., 7 1171-1188.
31. Wang, K. K. and Yuen, P. W. (1997). Development and therapeutic potential of calpain inhibitors. Adv. Pharmacol., 37 117-152.
32. Leung-Toung, R.; Zhao, Y.; Li, W.; Tam, T. F.; Karimiam, K. and Spino, M. (2006). Thiol proteases: inhibitors and potential therapeutic targets. Curr. Med. Chem., 13 547-581.
33. Barrett, A. J.; Kembhavi, A. A.; Brown, M. A.; Kirschke, H.; Knight, C. G.; Tamai, M. and Hanada, K. (1982). L-trans-epoxysuccinyl-leucylamido(4-guanidino) butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem. J., 201 189-198.
34. Sasaki, T.; Kikuchi, T.; Yumoto, N.; Yoshimura, N. and Murachi, T. (1984). Comparative specificity and kinetic studies on porcine calpain I and calpain II with naturally occurring peptides and synthetic fluorogenic substrates. J. Biol. Chem., 259 12489-12494.
35. Yano, Y.; Shiba, E.; Kambayashi, J.; Sakon, M.; Kawasaki, T.; Fujitani, K.; Kang, J. and Mori, T. (1993). The effects of calpeptin (a calpain specific inhibitor) on agonist induced microparticle formation from the platelet plasma membrane. Thromb Res., 71 385-396.
36. Mehdi, S.; Angelastro, M. R. and Wiseman, J. S. (1988). Inhibition of the proteolysis of rat erythrocyte membrane proteins by a synthetic inhibitor of calpain. Biochem. Biophys. Res. Commun., 157 1117-1123.
37. Inoue, J.; Nakamura, M.; Cui, Y. S.; Sakai, Y.; Sakai, O.; Hill. J. R.; Wang, K. K. and Yuen, P. W. (2003). Structure-activity relationshio study and drug profile of N-(4fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor. J. Med. Chem., 46 868-871.
38. Sasaki, T.; Kishi, M.; Saito, M.; Tanaka, T.; Higuchi, N.; Kominami, F.; Katunuma, N. and Murachi, T. (1990). Inhibitory effect of di-and tripeptidyl aldehydes on calpains and cathepsins. J. Enzyme Inhib. 3: 195-201.
39. Harbeson, S. L.; Abelleira, S. M.; Akiyama, A.; Barrett, R.; Carroll, R, M.; Straub, J. A.; Tkacz, J. N.; Wu, C.and Musso, G. F. (1994). Stereospecific synthesis of peptidyl alpha-keto amides as inhibitors of calpain. J. Med. Chem., 37 2918-2929.
40. Trumbeckaite. S.; Neuhof, C.; Zierz, S. and Gellerich. F. N. (2003). Calpain inhibitor (BSF 409425) diminishes ischemia/reperfusion-induced damage of rabbit heart mitochondria. Biochem. Pharmacol., 65 911-916.
41. Lubisch, W.; Beckenbach, F.; Bopp, S.; Hoffmann, H. P.; Kartal, A.; Kastel, C.; Lindner, T.; Metz-Garrecht, M.; Reeb, J.; Regner, F.; Vierling, M. and Möller, A. (2003). Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: discovery of potent water-soluble calpain inhibitors with oral bioavailability. J. Med. Chem., 46 2404-2412.
42. Neffe, A. T. and Abell, A. D. (2005). Developments in the design and synthesis of calpain inhibitors. Curr. Opin. Drug Discov. Dev., 8 684-700.
43. Wang, K. K.; Nath, R.; Posner, A.; Raser, K. J.; Buroker-Kilgore, M.; Hajimohammadreza, I.; Probert, A. W. Jr.; Marcoux, F. W.; Ye, Q.; Takano, E.; Hatanaka, M.; Maki, M.; Caner, H.; Collins, J. L.; Fergus, A.; Lee, K. S.; Lunney, E. A.; Hays, S. J. and Yuen, P. (1996). An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proc. Natl. Acad. Sci. USA, 93 6687-6692.
44. Posner, A.; Raser, K. J.; Hajimohammadreza, I.; Yuen, P. W. and Wang, K. K. (1995). Aurintricarboxylic acid is an inhibitor of mu-and m-calpain. Biochem. Mol. Biol. Int., 36 291-299.
45. Gil-Parrado, S.; Assfalg-Machleidt, I.; Fiorino, F.; Deluca, D.; Pfeiler, D.; Schaschke, N.; Moroder, L. and Machleidt, W. (2003). Calpastatin exon 1B-derived peptide, a selective inhibitor of calpain: enhancing cell permeability by conjugation with penetratin. Biol. Chem., 384 395-402.
46. Jiao, W.; McDonald, Q.; Coxon, J. M. and Parker, E. J. (2010). Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain. Biochemistry, 49 5533-5539.
47. Pietsch, M.; Chua, K. C. and Abell, A. D. (2010). Calpains: attractive targets for the development of synthetic inhibitors. Curr. Top. Med. Chem., 10 270-293.
48. McGhee, R. B. and Cosgrove, W. B. (1980). Biology and physiology of the lower Trypanosomatidae. Microbiol. Rev., 44 140-173.
49. Vickerman, K. (1994). The evolutionary expansion of the trypanosomatid flagellates. Int. J. Parasitol., 24 1317-1331.
50. De Souza, W.; Attias, M. and Rodrigues, J. C. F. (2009). Particularities of mitochondrial structure in parasitic protists (Apicomplexa and Kinetoplastida). Int. J. Biochem. Cell Biol., 41 2069-2080.
51. Handman, E. (1999). Cell biology of Leishmania. Adv. Parasitol. 44, 1-39.
52. De Souza, W. (2002). Basic cell biology of Trypanosoma cruzi. Curr. Pharmaceut. Des. 8, 269-285.
53. Matthews, K. R. (2005). The developmental cell biology of Trypanosoma brucei. J. Cell Sci. 118, 283-290.
54. Camargo, E. P. (1999). Phytomonas and other trypanosomatid parasites of plants and fruit. Adv. Parasitol., 42 29-112.
55. Laveran, A. and Franchini, G. (1913). Infection expérimentales de mammifères par des flagellés du tube digestif de Ctenocephalus canis et a'Anopheles maculipennis. C. R. Acad. Sci., 157 744-747.
56. Dedet, J. P.; Roche, B.; Pratlong, F.; Cales-Quist, D.; Jouannelle, J.; Benichou, J. C. and Huerre, M. (1995). Diffuse cutaneous infection caused by a presumed monoxenous trypanosomatid in a patient infected with HIV. Trans. R. Soc. Trop. Med. Hyg., 89 644-646.
57. Jiménez, M. I.; López-Vélez, R.; Molina, R.; Cañavate, C. and Alvar, J. (1996). HIV co-infection with a currently non-pathogenic flagellate. Lancet, 347 264-265.
58. Pacheco, R. S.; Marzochi, M. C. A.; Pires, M. Q.; Brito, C. M. M.; Madeira, M. F. and Barbosa-Santos, E. G. O. (1998). Parasite genotypically related to a monoxenous trypanosomatid of dog's flea causing opportunistic infection in an HIV positive patient. Mem. Inst. Oswaldo Cruz, 93 531-537.
59. Chicharro, C. and Alvar, J. (2003). Lower trypanosomatids in HIV/AIDS patients. Ann. Trop. Med. Parasitol., 97 75-78.
60. Morio, F.; Reynes, J.; Dollet, M.; Pratlong, F.; Dedet, J. P. and Ravel, C. (2008). Isolation of a protozoan parasite genetically related to the insect trypanosomatid Herpetomonas samuelpessoai from a human immunodeficiency virus-positive patient. J. Clin. Microbiol., 46 3845-3847.
61. Santos, A. L. S.; Branquinha, M. H. and d'Avila-Levy, C. M. (2006). The ubiquitous gp63-like metalloprotease from lower trypanosomatids: in the search for a function. An. Acad. Bras. Ciênc., 78 687-714.
62. Santos, A. L. S.; d'Avila-Levy, C. M.; Elias, C. G. R.; Vermelho, A. B. and Branquinha, M. H. (2007). Phytomonas serpens immunological similarities with the human trypanosomatid pathogens. Microbes Infect., 9 915-921.
63. Fairlamb, A. H. (2003). Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol., 19 488-494.
64. Cavalli, A. and Bolognesi, M. L. (2009). Neglected tropical diseases: multi-targetdirected ligands in the search for novel lead candidates against Trypanosoma and Leishmania. J. Med. Chem., 52 7339-7359.
65. McKerrow, J. H.; Doyle, P. S.; Engel, J. C.; Podust, L. M.; Robertson, S. A.; Ferreira, R.; Saxton, T.; Arkin, M.; Kerr, I. D.; Brinen, L. S. and Craik, C. S. (2009). Two approaches to discovering and developing new drugs for Chagas disease. Mem. Inst. Oswaldo Cruz, 104 263-269.
66. Wilkinson, S. R. and Kelly, J. M. (2009). Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev. Mol. Chem., 11 1-24.
67. Urbina, J. A. (2010). Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Trop., 115 55-68.
68. McKerrow, J. H.; Sun, E.; Rosenthal, P. J. and Bouvier, J. (1993). The proteases and pathogenicity of parasitic protozoa. Annu. Rev. Microbiol., 47 821-853.
69. Cazzulo, J. J. (2002). Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Chagas disease. Curr. Top. Med. Chem., 2 1261-1271.
70. Klemba, M. and Goldberg, D. E. (2002). Biological roles of proteases in parasitic protozoa. Annu. Rev. Biochem., 71 275-305.
71. Lalmanach, G.; Boulangé, A.; Serveau, C.; Lecaille, F.; Scharfstein, J.; Gauthier, F. and Authié, E. (2002). Congopain from Trypanosoma congolense: drug target and vaccine candidate. Biol. Chem., 383 739-749.
72. Yao, C. (2010). Major surface protease of trypanosomatids: one size fits all? Infect. Immun., 78 22-31.
73. Vermelho, A. B.; Giovanni-de-Simone, S.; d'Avila-Levy, C. M.; Santos, A. L. S.; Melo, A. C. N.; Silva Jr, F. P.; Bon, E. P. S. and Branquinha, M. H. (2007). Trypanosomatidae peptidases: a target for drugs development. Curr. Enz. Inhib., 3 19-48.
74. Vermelho, A. B.; Branquinha, M. H.; d'Ávila-Levy, C. M.; Santos, A. L. S.; Paraguai de Souza, E. and Nogueira de Melo, A. C. (2010). Biological roles of peptidases in trypanosomatids. Open Parasitol. J., 4 5-23.
75. Atkinson, H. J.; Babbitt, P. C. and Sajid, M. (2009). The global cysteine peptidase landscape in parasites. Trends Parasitol., 25 573-581.
76. Ersfeld, K.; Barraclough, H. and Gull, K. (2005). Evolutionary relationships and protein domain architecture in an expanded calpain superfamily in kinetoplastid parasites. J. Mol. Evol., 61 742-757.
77. Pils, B. and Schultz, J. (2004). Inactive enzyme-homologues find new function in regulatory processes. J. Mol. Biol. 340. 399-404.
78. Tonami, K.; Kurihara, Y.; Aburatani, H.; Uchijima, Y.; Asano, T. and Kurihara, H. (2007). Calpain 6 is involved in microtubule stabilization and cytoskeletal organization. Mol. Cell Biol., 27 2548-2561.
79. Olego-Fernandez, S.; Vaughan, S.; Shaw, M. K.; Gull, K. and Ginger, M. L. (2009). Cell morphogenesis of Trypanosoma brucei requires the paralogous, differentially expressed calpain-related proteins CAP5.5 and CAP5.5V. Protist, 160 576-590.
80. Hertz-Fowler, C.; Ersfeld, K. and Gull, K. (2001). CAP5.5, a life-cycle-regulated, cytoskeleton-associated protein is a member of a novel family of calpain-related proteins in Trypanosoma brucei. Mol. Biochem. Parasitol., 116 25-34.
81. Dear, N.; Matena, K.; Vingron, M. and Boehm, T. (1997). A new subfamily of vertebrate calpains lacking a calmodulin-like domain: implications for calpain regulation and evolution. Genomics, 45 175-184.
82. Matthews, K. R. and Gull, K. (1994). Evidence for an interplay between cell cycle progression and the initiation of differentiation between life cycle forms of African trypanosomes. J. Cell Biol., 125 1147-1156.
83. Liu, W.; Apagyi, K.; McLeavy, L.and Ersfeld, K. (2010). Expression and cellular localisation of calpain-like proteins in Trypanosoma brucei. Mol. Biochem. Parasitol., 169 20-26.
84. Giese, V.; Dallagiovanna, B.; Marchini, F. K.; Pavoni, D. P.; Krieger, M. A. and Goldenberg, S. (2008). Trypanosoma cruzi: a stage-specific calpain-like protein is induced after various kinds of stress. Mem. Inst. Oswaldo Cruz, 103 598-601.
85. Bonaldo, M. C.; Souto-Padron, T.; de Souza, W. and Goldenberg, S. (1988). Cell-substrate adhesion during Trypanosoma cruzi differentiation. J. Cell Biol., 106 1349-1358.
86. Sangenito, L. S.; Ennes-Vidal, V.; Marinho, F.A.; da Motta, F. F.; Santos, A. L. S.; d'Avila-Levy, C.M. and Branquinha, M. H. (2009). Arrested growth of Trypanosoma cruzi by the calpain inhibitor MDL28170 and detection of calpain homologues in epimastigote forms. Parasitology, 136 433-441.
87. Emori, Y. and Saigo, K. (1994) Calpain localization changes in coordination with actin-related cytoskeletal changes during early embryonic development of Drosophila. J. Biol. Chem., 269 25137-25142.
88. Contreras, V. T.; Lima, A. R. and Zorrilla, G. (1998). Trypanosoma cruzi: maintenance in culture modify gene and antigenic expression of metacyclic trypomastigotes. Mem. Inst. Oswaldo Cruz, 93 753-760.
89. Andrade, H. M.; Murta, S.M. F.; Chapeaurouge, A.; Perales, J.; Nirdé, P. and Romanha, A. (2008). Proteomic analysis of Trypanosoma cruzi resistance to benznidazole. J. Proteome Res., 7 2357-2367.
90. Miles, M.A.; Souza, A.; Povoa, M.; Shaw, J. J.; Lainson, R. and Toye, P. J. (1978). Isozymic heterogeneity of Trypanosoma cruzi in the first autochthonous patients with Chagas' disease in Amazonian Brazil. Nature, 272 819-821.
91. Souto, R. P.; Fernandes, O.; Macedo, A. M.; Campbell, D. A. and Zingales, B. (1996). DNA markers define two major phylogenetic lineages of Trypanosoma cruzi. Mol. Biochem. Parasitol., 83 141-152.
92. Kikuchi, S. A.; Sodré, C. K.; Kalume, D. E.; Elias, C. G. R.; Santos, A. L. S.; Soeiro, M. N.; Meuser, M.; Chapeaurouge, A.; Perales, J. and Fernandes, O. (2010). Proteomic analysis of two Trypanosoma cruzi zymodeme 3 strains. Exp. Parasitol., 126 540-551.
93. Brisse, S.; Dujardin, J. C. and Tibayrenc, M. (2000). Identification of six Trypanosoma cruzi lineages by sequence-characterised amplified region markers. Mol. Biochem. Parasitol., 111 95-105.
94. Macedo, A. M.; Machado, C. R.; Oliveira, R. P. and Pena, S. D. (2004). Trypanosoma cruzi: genetic structure of populations and relevance of genetic variability to the pathogenesis of Chagas disease. Mem. Inst. Oswaldo Cruz, 99 1-12.
95. Fernandes, O.; Santos, S.S.; Cupolillo, E.; Mendonça, B.; Derre, R.; Junqueira, A. C.; Santos, L. C.; Sturm, N. R.; Naiff, R. D.; Barret, T. V.; Campbell, D. A. and Coura, J.R. (2001). A mini-exon multiplex polymerase chain reaction to distinguish the major groups of Trypanosoma cruzi and T. rangeli in the Brazilian Amazon. Trans. R. Soc. Trop. Med. Hyg., 95 97-99.
96. Brandão, A. and Fernandes, O. (2006). Trypanosoma cruzi: mutation in 3'-untranslated region of calmodulin gene are specific for lineages T. cruzi I, T. cruzi II and zymodeme III isolates. Exp. Parasitol., 112 247-252.
97. Fampa, P.; Lisboa, C. V.; Jansen, A. M.; Santos, A. L. S. and Ramirez, M. I. (2008). Protease expression analysis in recently field-isolated strains of Trypanosoma cruzi: a heterogeneous profile of cysteine protease activities between TC I and TC II major phylogenetic groups. Parasitology, 135 1093-1100.
98. Fampa, P.; Santos, A. L. S. and Ramirez, M. I. (2010). Trypanosoma cruzi: ubiquity expression of surface cruzipain molecules in TCI and TCII field isolates. Parasitol. Res., 107 443-447.
99. Gomes, S. A. O.; Misael, D.; Silva, B. A.;, Feder, D.; Silva, C. S.; Gonçalves, T. C. M.; Santos, A. L. S. and Santos-Mallet, J. R. (2009). Major cysteine protease (cruzipain) in Z3 sylvatic isolates of Trypanosoma cruzi from Rio de Janeiro-Brazil. Parasitol. Res., 105 743-749.
100. Bhattacharya, J.; Dey, R. and Datta, S. C. (1993). Calcium dependent thiol protease caldonopain and its specific endogenous inhibitor in Leishmania donovani. Mol. Cell Biochem., 126 9-16.
101. Dey, R.; Bhattacharya, J. and Datta, S. C. (2006). Calcium-dependent proteolytic activity of a cysteine protease caldonopain is detected during Leishmania infection. Mol. Cell Biochem., 281 27-33.
102. d'Avila-Levy, C. M.; Marinho, F. A.; Santos, L. O.; Martins, J. L. M.; Santos, A. L. S. and Branquinha, M. H. (2006). Antileishmanial activity of MDL28170, a potent calpain inhibitor. Int. J. Antimicrob. Agents, 28 138-142.
103. Denny, P. W.; Field, M. C. and Smith, D.F. (2001). GPI-anchored proteins and glycoconjugates segregate into lipid rafts in kinetoplastida. FEBS Lett., 491 148-153.
104. Salotra, P.; Duncan, R. C.; Singh, R.; Raju, B. V. S.; Sreenivas, G. and Nakhasi, H. L. (2006). Upregulation of surface proteins in Leishmania donovani isolated from patients of post kala-azar dermal leishmaniasis. Microbes Infect., 8 637-644.
105. Vergnes, B.; Gourbal, B.; Gorard, I.; Sundar, S.; Drummelsmith, J. and Ouellette, M. (2007). A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol. Cell. Proteomics, 6 88-101.
106. Saxena, A.; Worthey, E. A.; Yan, S.; Leland, A.; Stuart, K. D. and Myler, P. J. (2003). Evaluation of differential gene expression in Leishmania major Friedlin procyclics and metacyclics using DNA microarray analysis. Mol. Biochem. Parasitol., 129 103-114.
107. Tull, D.; Vince, J. E.; Callaghan, J. M.; Naderer, T.; Spurck, T.; McFadden, G. I.; Currie, G.; Ferguson, K.; Bacic, A. and McConville, M. J. (2004) SMP-1, a member of a new family of small myristoylated proteins in kinetoplastid parasites, is targeted to the flagellum membrane in Leishmania. Mol. Biol. Cell, 15 4775-4786.
108. d'Avila-Levy, C. M.; Souza, R. F.; Gomes, R. C.; Vermelho, A. B. and Branquinha, M. H. (2003). A novel extracellular cysteine proteinase from Crithidia deanei. Arch. Biochem. Biophys., 420 1-8.
109. Pereira, F. M.; Elias, C. G. R.; d'Avila-Levy, C. M.; Branquinha, M. H. and Santos, A. L. S. (2009). Cysteine peptidases in Herpetomonas samuelpessoai are modulated by temperature and dimethylsulfoxide-triggered differentiation. Parasitology, 136 45-54.
110. Castellanos, G. B.; Angluster, J. and de Souza, W. (1981). Induction of differentiation in Herpetomonas samuelpessoai by dimethylsulphoxide. Acta Trop., 38 29-37.
111. Ennes-Vidal, V.; Menna-Barreto, R. F.; Santos, A. L.; Branquinha, M. H. and d'Avila-Levy, C. M. (2010). Effects of the calpain inhibitor MDL28170 on the clinically relevant forms of Trypanosoma cruzi in vitro. J. Antimicrob. Chemother., 65 1395-1398.
112. Sant'Anna, C.; Nakayasu, E. S.; Pereira, M. G.; Lourenço, D.; de Souza, W.; Almeida, I. C. and Cunha-e-Silva, N. L. (2009). Subcellular proteomics of Trypanosoma cruzi reservosomes. Proteomics, 9 1782-1794.
113. Soares, M. J. (1999). The reservosome of Trypanosoma cruzi epimastigotes: an organelle of the endocytic pathway with a role on metacyclogenesis. Mem. Inst. Oswaldo Cruz 94 Suppl, 1 139-141.
114. Ennes-Vidal, V.; Menna-Barreto, R. F.; Santos, A. L. S.; Branquinha, M. H. and d'Avila-Levy, C. M. (2010). MDL28170, a potent calpain inhibitor, affects Trypanosoma cruzi metacyclogenesis, ultrastructure and attachment to the luminal midgut surface of Rhodnius prolixus. Submitted manuscript.
115. Branquinha, M. H.; Vermelho, A. B.; Goldenberg, S.; Bonaldo, M. C. (1996). Ubiquity of cysteine-and metalloproteinase activities in a wide range of trypanosomatids. J. Eukaryot. Microbiol., 43 131-135.
116. Santos, A. L. S.; Abreu, C. M.; Alviano, C. S. and Soares, R. M. A. (2005). Use of proteolytic enzymes as an additional tool for trypanosomatid identification. Parasitology, 130 79-88.
117. Yong, V.; Schmitz, V.; Vannier-Santos, M. A.; Lima, A.P. C. A.; Lalmanach, G.; Juliano, L.; Gauthier, F. and Scharfstein, J. (2000). Altered expression of cruzipain and a cathepsin B-like target in a Trypanosoma cruzi cell line displaying resistance to synthetic inhibitors of cysteine-proteinases. Mol. Biochem. Parasitol., 109 47-59.
118. Green, D. R. (2000). Apoptotic pathways: paper wraps stone blunts scissors. Cell, 102 1-4.
119. Green, D. R.; Knight, R. A.; Melino, G.; Finazzi-Agro, A. and Orrenius, S. (2004). Ten years of publication in cell death. Cell Death Differ., 11 2-3.
120. Bras, M.; Queenan, B. and Susin, S. A. (2005). Programmed cell death via mitochondria: different modes of dying. Biochemistry (Moscow), 70 231-239.
121. Lee, N.; Bertholet, S.; Debrabant, A.; Muller, J.; Duncan, R. and Nakhasi, H. L. (2002). Programmed cell death in the unicellular protozoan parasite Leishmania. Cell Death Differ., 9 53-64.
122. Sereno, D.; Holzmuller, P.; Mangot, I.; Cuny, G.; Ouaissi, A. and Lemesre, J. L. (2001). Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrob. Agents Chemother., 45 2064-2069.
123. 2+-dependent cell death pathway in the unicellular organism Trypanosoma brucei brucei. Biochem. J., 340 33-40.
124. Green, S. J.; Crawford, R. M.; Hockmeyer, J. T.; Meltzer, M. S. and Nacy, C. A. (1990). Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J. Immunol., 145 4290-4297.
125. Panaro, M. A.; Acquafredda, A.; Lisi, S.; Lofrumento, D. D.; Trotta, T.; Satalino, R.; Saccia, M.; Mitolo, V. and Brandonisio, O. (1999). Inducible nitric oxide synthase and nitric oxide production in Leishmania infantum-infected human macrophages stimulated with interferon-gamma and bacterial lipopolysaccharide. Int. J. Clin. Lab. Res., 29 122-127.
126. Sisto, M.; Brandonisio, O.; Panaro, M. A.; Acquafredda, A.; Leogrande, D.; Fasanella, A.; Trotta, T.; Fumarola, L. and Mitolo, V. (2001). Inducible nitric oxide synthase expression in Leishmania-infected dog macrophages. Comp. Immunol. Microbiol. Infect. Dis., 24 247-254.
127. Holzmuller, P.; Bras-Gonçalves, R.and Lemesre, J. L. (2006). Phenotypical characteristics, biochemical pathways, molecular targets and putative role of nitric oxide-mediated programmed cell death in Leishmania. Parasitology 132 Suppl, S19-S32.
128. Holzmuller, P.; Sereno, D.; Cavaleyra, M.; Mangot, I.; Daulouede, S.; Vincendeau, P. and Lemesre, J. L. (2002). Nitric oxide-mediated proteasome-dependent oligonucleosomal DNA fragmentation in Leishmania amazonensis amastigotes. Infect. Immun., 70 3727-3735.
129. Paris, C.; Loiseau, P. M.; Bories, C. and Breard, J. (2004). Miltefosineinduces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob. Agents Chemother., 48 852-859.
130. McKerrow, J. H.; Rosenthal, P. J.; Swenerton, R. and Doyle, P. 2008. Development of protease inhibitors for protozoan infections. Curr. Opin. Infect. Dis., 21 668-672.